Feed AUPH
AU
Aurinia Pharmaceuticals Inc. AUPH · NASDAQ
$16.66 -3.22% (-$0.56)
Depth
- Market cap
- $2.29B
- Enterprise value
- $2.17B
- P/E
- 7.3x
- Forward P/E
- 17.4x
- PEG
- 0.0x
- P/S
- 7.4x
- P/FCF
- 13.2x
- EV/EBITDA
- 11.5x
- ROIC
- 41.7%
- Gross margin
- 90.4%
- Net margin
- 100.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -0.6x
- Beta
- 1.41
- Free float
- 97.1%
Sector
Healthcare
Industry
Biotechnology
CEO
Kevin C. Tang
Employees
128
Headquarters
Edmonton
Valuation
Is today's price reasonable?
- What speaks for it: The share price is below the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 28% a year over the last 3 years.
- What to watch: Earnings per share swing sharply from year to year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 101 USD is left as net profit.
- What speaks for it: It earns 42 USD a year on every 100 USD of invested capital.
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number